Summary: Plasma levels of tricyclic antidepressant drugs vary considerably between individuals receiving the same amount of drug. The bearing of this variation on the occurrence of subjective side effects was investigated in 40 psychiatric inpatients with depressive disorders. Plasma levels were determined before and during four weeks of treatment with nortriptyline 50 mg. three times a day and patients were rated for subjective side effects, the assessors being unaware of the plasma levels of the drug.
Introduction
During continuous treatment with tricyclic antidepressant drugs the drug concentration in plasma increases successively until a plateau is reached. This plateau level varies considerably between individuals . For nortriptyline a range from 8 to 78 ng./ml. was observed in healthy volunteers after eight days' administration of 0-2 mg. /kg. body weight three times daily (Alexanderson et al., 1969) . The bearing of this variation on the clinical effects of the drug has not previously been investigated, but preliminary observations (Sjdqvist et al., 1968 ndicated that a high plasma level might be of importance for the occurrence of side effects.
The aim of the present investigation was to study the occurrence of subjective side effects of nortriptyline, a monomethylated tricyclic antidepressant, in relation to the plasma level of the drug. Nortriptyline was used because of its known pharmacokinetic properties-that is, steady-state kinetics and little interindividual variation in plasma protein binding . Nortriptyline is active per se, and there is no indication that its main metabolites in man, 10-OH-nortriptyline and desmethylnortriptyline (this laboratory, unpublished), contribute to the therapeutic action (Sj6qvist et al., 1969; Borga' et al., 1970) .
Side effects of tricyclic antidepressant drugs are often reported in connexion with evaluations of their therapeutic efficacy-for example, Rose et al. (1965) and Stewart and Mitchell (1968) . Some of the side effects attributed to the drug, such as dryness of mouth, constipation, and fatigue, are, however, also well-recognized symptoms of depression. Others, sluch as tremor and increased perspiration, are somatic manifestations of anxiety (Hamilton, 1959) toms similar to side effects may exist before treatment, as was shown by Green (1964) , who found a variety of "side effect symptoms" present in non-treated "well" subjects as well as in medical patients not under drug treatment. These symptoms tended to be accentuated by placebo treatment.
Quantitative ratings of side effects are thus likely to include symptoms of non-pharmacological origin. The importance of relating "side effect symptoms" during drug treatment to the incidence of symptoms during a control period when no drug has been given, or preferably when no drug has been found in the body fluids with sensitive analytical methods, is further shown by the investigations of Berry and Turner (1968) . In a cross-over trial they found that patients excreted significant amounts of psychotropic drugs during a period when these drugs were not administered by the physician.
Patients and Methods
Forty-two depressed inpatients were studied. The material was classified into "neurotic" (8 men and 9 women, age range 25-63, mean age 41-5 years) and "endogenous" (8 men and 17 women, age range 25-72, mean age 53-6 years) depressions. The classification was made after a clinical evaluation. Endogenous depression was operationally defined as a disease characterized by the following features: (1) lowering of mood, usually without adequate psychological cause, (2) retardation, (3) diurnal variation of symptoms with amelioration in the afternoon, and (4) early awakening, in accordance with the description of Cronholm and Ottosson (1960) . The "neurotic" group included patients with various types of depression not exhibiting these features. The severity of depression was such as to warrant admission to hospital.
Drug Regimen.-Nortriptyline 50 mg. was given by mouth thrice daily for four weeks after a period of four to seven days of placebo administration. The placebo tablets consisted of lactose. The tablets were given at 06.00, 14.00, and 22.00 hours, and the patients were routinely observed to ingest the drug. With the exception of hypnotics (pentobarbitone or glutethimide) and occasional doses of sedatives (diazepam, meprobamate), which do not interfere in the method used to assay nortriptyline, no additional drugs were allowed. Blood and urine analyses for barbiturates, phenothiazines, and meprobamate performed during the placebo period and every other week during nortriptyline therapy showed no discrepancies to the prescribed treatment.
Determination of Plasma Level of Nortriptyline.-Plasma levels of nortriptyline were determined during the placebo period and twice weekly during treatment with nortriptyline according to the principles of Hammer and Brodie (1967) as further described by Sjoqvist et al. (1969) . Blood samples were drawn at 13.00 hours, collected in heparinized tubes, stored at 40 C. and centrifuged within one hour at 600 g. Plasma duplicates, 2 ml. each, were acidified with 0-5 ml. of 01 N HCl and stored frozen at -200C. until analysed.
Ratings.-The patients were rated for side effects once weekly, starting during the placebo period, on a rating scale, designed for the purpose ( origin. Patients with endogenous depression were also rated for severity of depression according to a rating scale designed by Gronholm and Ottosson (1960) . Those (Fig. 1) . This difference is, however, not significant'in a three-way analysis of variance (Winer, 1962 ) (F= 1.039), nor is there any significant variation within weeks (F=2-370).
Side Effects
The percentages of patients who have any of the 11 rated "side effects" are shown in Table II . If no account is taken of symptoms occurring during placebo therapy and the severity of symptoms, conclusions regarding the incidence of side effects may be misleading.
In most cases the side effects of nortriptyline were rather moderate. In two cases out of 40 there were, however, more alarming side effects. In one of these cases, a 44-year-old woman, the dosage had to be reduced because the patient c I CO. 1I. The raw side effect scores on placebo and active therapy appear in Table III A. This shows a slight but significant increase in side effects during the first and second weeks of active therapy as compared with placebo. During the third and fourth weeks the side effect scores diminished and were lower than on placebo, though not significantly so (Table  IV A) .
Throughout the study there was a significant correlation between raw side effect scores and severity of depression in the endogenous depressions ( (Fig. 2, Table III B) . The scores of weeks 3 and 4 are significantly lower than those of week 1; in fact the mean side effect score for the fourth week is negative (Tables III B, and IV B) .
Relationship of Side Effects to Plasma Level of Nortriptyline.-The two above-mentioned patients with severe side effects had the highest plasma levels in the material (maximum values 340 and 235 ng./ml. in the woman and man respectively). There was a significant correlation between corrected side effect scores and plasma level of nortriptyline during the first three weeks of treatment (Table VI  A) . Though all patients received the same amount of nortriptyline, there is still a variation in dosage due to differences in body weight (range 1-69-3 06 mg./kg.). There is, however, no correlation between dosage in mg./kg. body weight and corrected side effect scores (Table VI B) .
Discussion
The plateau plasma levels of no~rtriptyline are under genetic control and presumably determined by the rate of metabolism of the drug (Alexanderson et al., 1969) . The finding that occasional patients develop extremely high plasma levels of nortriptyline on a conventional dosage suggests that there may be genetic polymorphisms forming a polygenic system controlling the metabolism of the drug, a hypothesis which is at present being evaluated.
The tendency of side effects to diminish with time accords with clinical experience. It might be due to the development of receptor tolerance to the peripheral effects of the drug, since there is no corresponding trend in the plasma levels. Psychological factors, such as decreased awareness of side effects with amelioration of the depression, may also contribute. This would be in keeping with the finding that after successful electric convulsion treatment depressed patients tend to judge their memory as improved, independently of objective change (Cronholm and Ottosson, 1963) .
The inhibitory effect of tricyclic antidepressants on the neuronal uptake of various monoamines within the central nervous system is thought to be closely related to the antidepressant effect (Carlsson, 1965; Schildkraut and Ketv, 1967) . Controlled studies are in progress on the relationship between plasma level and therapeutic efficacy of the drug. So far, however, there is no evidence that very high plasma levels (over, say, 100 ng./ml.) are necessary for a therapeutic effect, and it therefore becomes important to reduce dosage in patients who develop high plasma levels and so avoid a potentially harmful accumulation of the drug. This is particularly desirable in elderly patients in whom cardiotoxicity could reasonably be expected to have more serious consequences. In view of the many factors that contribute to the occurrence of subjective side effects in the individual patient, it is, however, questionable whether the side effects could be used as criteria to determine optimal dosage.
Detailed analysis of the rating protocols revealed no straightforward correlation between any particular side effect and the plasma level of nortriptyline. Such side effects as dryness of mouth and constipation may be due both to an anticholinergic effect and to a central adrenergic inhibition of parasympathetic activity. In this connexion blockade of tyramine pressor effects by nortriptyline in man is strongly correlated to the plasma level of the drug but not to the dose (Freyschuss et al., 1970b (Mullinger, 1968) . The response is often incomplete, however, even if large doses are given throughout the day (Jordan and Grossman, 1959) , and even if sodium bicarbonate is added (Glaessner and Sigel, 1904; Veeger et al., 1962; Haro and Faloon, 1964) . Plant and bacterial enzymes have been incorporated in some pancreatic preparations to improve their effectiveness (Goebell and Bode, 1969) . A mixture of bromelains and pancreatin is available in two preparations (Nusser and Donath, 1968; Schultis and Wagner, 1968) , one of which is Nutrizym (Merck). Bromelains is a mixture of proteolytic enzymes found in the stem of the pineapple (Ananas comosus); it has maximal proteolytic activity between pH 3 and 8, and is stable at pH 2-0 for a short period. Studies in vitro have shown that its effect in the digestion of casein at pH 3-3 is similar to that of pepsin and at pH 6-0 is similar to that of trypsin (Hennrich et al., 1965) . Nutrizym has an enteric-coated core containing concentrated pancreatic extract, surrounded by a layer of bromelains and a sugar coating.
We describe here a cross-over trial comparing Nutrizym with Pancrex V forte (pancreatin, B.P.), which is the most widely used of the pancreatic replacement preparations available in the British Isles. The effect of the added bromelains was also investigated by including in the trial a period on Nutrizym core, which was identical in appearance to Nutrizym but contained enteric-coated pancreatin alone. 
Design of Trial
Fourteen outpatients (3 female and 11 male) were admitted to the trial: two middle-aged patients with chronic pancreatitis and 12 (aged 15-29) with cystic fibrosis. The latter were chosen because they had considerable steatorrhoea even while taking Pancrex V forte (10 patients) or pancreatin granules (two patients). Other treatment was unaltered during the trial. Each patient was in the trial for three months and received Pancrex, Nutrizym, and Nutrizym core, each for one month in random order. A tablet of Nutrizym contained 50 mg. of bromelains. The amount of pancreatin in a tablet of Nutrizym was greater than in Pancrex V forte, and the doses given with each of the three main meals in a day were either three tablets of Pancrex V forte or two tablets of the Nutrizym preparations. At the end of the trial the three preparations were assayed in vitro. Each tablet of Nutrizym and Nutrizym core was found to contain: trypsin 2,500 units, lipase 8,100 units, and amylase 18,000 units; the corresponding figures for Pancrex V forte were 1,230, 4,000, and 9,600 units respectively.
